Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Outlook for 2025 earnings raisedRoche expects an increase in Group sales in the mid single digit range (CER). Core earnings per...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated population...
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III R...
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1IMvigor011 ...
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research...
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment...
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study...
Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in e...
